Unknown

Dataset Information

Including non-concurrent control patients in the analysis of platform trials: is it worth it?


ABSTRACT:

Background

Platform trials allow adding new experimental treatments to an on-going trial. This feature is attractive to practitioners due to improved efficiency. Nevertheless, the operating characteristics of a trial that adds arms have not been well-studied. One controversy is whether just the concurrent control data (i.e. of patients who are recruited after a new arm is added) should be used in the analysis of the newly added treatment(s), or all control data (i.e. non-concurrent and concurrent).

Methods

We investigate the benefits and drawbacks of using non-concurrent control data within a two-stage setting. We perform simulation studies to explore the impact of a linear and a step trend on the inference of the trial. We compare several analysis approaches when one includ

SUBMITTER: Lee KM 

PROVIDER: S-EPMC7315495 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature